28/05/2007 9:34AM To present at Bank of America Health Care...

28/05/2007 9:34AM To present at Bank of America Health Care Conference


Prana Biotechnology to Present at the
Bank of America 2007 Health Care Conference
MELBOURNE, Australia ? May 28, 2007 ? Prana Biotechnology Limited (NASDAQ: PRAN /
ASX: PBT), a biopharmaceutical company focused on the research and development of treatments
for neurodegenerative disorders, today announced that Steven Targum, MD, Chief Medical Advisor,
will present at the Bank of America 2007 Health Care Conference in Las Vegas on Thursday, May
31 at 3:20 p.m. PST (6:20 p.m. EST and Friday, June 1 at 8:20 a.m. in Melbourne). The Conference
will be held on May 30 ? June 1 at The Four Seasons Hotel in Las Vegas, NV.
During the presentation, Dr. Targum will address the current status of Prana?s development program
targeting Alzheimer?s disease (AD) and related disorders, with particular emphasis on PBT2
presently studied in Phase IIa clinical trials in AD patients in Europe.
Dr. Targum?s presentation will be web cast live and a replay will be available following the
conclusion. To access the live and encore presentations, visit the Prana web site,
www.pranabio.com. The presentation will be archived on the Company site until June 15, 2007.
In April, the Company announced that Dr. Targum and Axel Unterbeck PhD, two US-based
pharmaceutical executives, joined Prana as Chief Medical Advisor and Chief Strategic Advisor,
respectively. Dr. Targum also is a member of the Prana Research & Development Advisory Board.
About the two US members of the Prana team:
Axel Unterbeck, PhD, Chief Strategic Advisor ? Dr. Unterbeck has vast experience in CNS research
and drug development as well as business development. In the 1980?s he was integral in the cloning
of APP, the precursor protein to beta-amyloid, currently the main therapeutic target of most
Alzheimer treatment strategies. In addition, Dr. Unterbeck has had a distinguished career in
executive management roles within the pharmaceutical industry, and more recently in the
establishment and building of the biotech company, Memory Pharmaceuticals. Dr. Unterbeck also
serves as an Executive-in-Residence with Oxford Bioscience Partners, a leading Boston-based
health care VC fund.
Steven D. Targum, MD, Chief Medical Advisor ? Dr. Targum is a US-based clinician with extensive
clinical trial expertise, having conducted over 200 trials in the area of CNS. Dr. Targum was the
founder of a global rater training company for CNS trials and currently consults to the
pharmaceutical industry on improved protocol design and achievement of effective signals in phase
II clinical trials. He is an Executive-in-Residence with Oxford Bioscience Partners and a consultant
in psychiatry at the Massachusetts General Hospital in Boston, Massachusetts.

http://imagesignal.comsec.com.au/asxdata/20070528/pdf/00724553.pdf